These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Activation of the E2F transcription factor by cyclin D1 is blocked by p16INK4, the product of the putative tumor suppressor gene MTS1. Schulze A; Zerfass K; Spitkovsky D; Henglein B; Jansen-Dürr P Oncogene; 1994 Dec; 9(12):3475-82. PubMed ID: 7970707 [TBL] [Abstract][Full Text] [Related]
10. Lack of mutation in the cyclin-dependent kinase inhibitor, p19INK4d, in tumor-derived cell lines and primary tumors. Zariwala M; Xiong Y Oncogene; 1996 Nov; 13(9):2033-8. PubMed ID: 8934552 [TBL] [Abstract][Full Text] [Related]
11. Regulation and function of the cyclin-dependent kinase inhibitor p16CDKN2. Peters G; Parry D; Hara E; Hall M; Bates S; Palmero I Leukemia; 1997 Apr; 11 Suppl 3():352-5. PubMed ID: 9209387 [TBL] [Abstract][Full Text] [Related]
12. Molecular analysis of the cyclin-dependent kinase inhibitor genes p15INK4b/MTS2, p16INK4/MTS1, p18 and p19 in human cancer cell lines. Gemma A; Takenoshita S; Hagiwara K; Okamoto A; Spillare EA; McMemamin MG; Hussain SP; Forrester K; Zariwala M; Xiong Y; Harris CC Int J Cancer; 1996 Nov; 68(5):605-11. PubMed ID: 8938142 [TBL] [Abstract][Full Text] [Related]
13. Highly frequent homozygous deletion of the p16 gene in esophageal cancer cell lines. Igaki H; Sasaki H; Kishi T; Sakamoto H; Tachimori Y; Kato H; Watanabe H; Sugimura T; Terada M Biochem Biophys Res Commun; 1994 Sep; 203(2):1090-5. PubMed ID: 8093026 [TBL] [Abstract][Full Text] [Related]
14. Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas--relationship to amplification and mRNA levels of CDK4 and CCND1. Maelandsmo GM; Berner JM; Flørenes VA; Forus A; Hovig E; Fodstad O; Myklebost O Br J Cancer; 1995 Aug; 72(2):393-8. PubMed ID: 7640224 [TBL] [Abstract][Full Text] [Related]
15. Recent progress in molecular mechanisms of leukemogenesis: the cyclin-dependent kinase 4-inhibitor gene in human leukemias. Hirai H; Ogawa S; Hangaishi A; Takahashi T; Kurokawa M; Mitani K; Ueda R; Yazaki Y Leukemia; 1997 Apr; 11 Suppl 3():358-60. PubMed ID: 9209389 [TBL] [Abstract][Full Text] [Related]
16. Deletion and transfection analysis of the p15/MTS2 gene in malignant gliomas. Tenan M; Benedetti S; Finocchiaro G Biochem Biophys Res Commun; 1995 Dec; 217(1):195-202. PubMed ID: 8526910 [TBL] [Abstract][Full Text] [Related]
17. Coincidental alterations of p16INK4A/CDKN2 and other genes in human lung cancer cell lines. Fujishita T; Mizushima Y; Kashii T; Kobayashi M Anticancer Res; 1998; 18(3A):1537-42. PubMed ID: 9673367 [TBL] [Abstract][Full Text] [Related]
18. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924 [TBL] [Abstract][Full Text] [Related]
19. Growth suppression by p16ink4 requires functional retinoblastoma protein. Medema RH; Herrera RE; Lam F; Weinberg RA Proc Natl Acad Sci U S A; 1995 Jul; 92(14):6289-93. PubMed ID: 7603984 [TBL] [Abstract][Full Text] [Related]